Podcasts about Hodgkin lymphoma

Back in October of 2024, Dave Coulier was diagnosed with stage 3 non-Hodgkin Lymphoma. AND A little girl with autism reminds others of Snow White and her connection to animals. To see videos and photos referenced in this episode, visit GodUpdates! https://www.godtube.com/blog/candace-cameron-bure-shares-news.html https://www.godtube.com/blog/reminds-others-of-snow-white.html Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

Episode Summary:In this episode of The Patient from Hell, we sit down with Samira and Dr. Samantha, two storytellers who delve into the power of personal narratives, cultural identity, and representation. They share their experiences navigating different spaces, finding their voices, and embracing authenticity. Whether you're interested in storytelling, personal growth, or the intersections of culture and identity, this episode offers deep insights and inspiration.About Our Guest:Dr. Samantha Siegel is an onco-pcp and survivorship physician at Kaiser Permanente. She has survived relapsed/refractory Hodgkin Lymphoma, including an autologous bone marrow transplant in June 2022. This has made her passionate about integrative oncology, AYA survivorship, longterm toxicities, returning to work after cancer and more. Dr. Siegel is the cofounder of PCP-ONC CARES program, a longitudinal cancer survivorship care model beginning at diagnosis and she serves as the current director of Cancer Survivorship for Kaiser San Francisco. She is the host of AIM at Melanoma's supportive cancer care podcast, “Beyond the Clinic.” Dr. Siegel is focused on elevating cancer survivorship to a distinct board certification status. She lives in Davis with her husband, three kids and energetic dog. They enjoy outdoor activities and plant-based living.Key Highlights:[00:10:30] The Power of Storytelling in Identity: Sam and Samira discuss how personal experiences shape the stories we tell and the impact storytelling has on self-identity and cultural understanding.[00:22:45] Challenges in Representation: They share their experiences with representation in the media and the barriers they've faced in telling authentic stories.[00:35:00] Embracing Authenticity in Creative Work: A conversation about the importance of staying true to oneself and how authenticity can lead to more meaningful storytelling and connection.Key Moments:[00:02:15] - Introduction to Sam and Samira[00:10:30] - How personal experiences shape storytelling[00:22:45] - Overcoming challenges in representation[00:35:00] - The impact of authenticity in creative work[00:48:20] - Closing thoughts and takeawaysConnect with Us: Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI ⁠study⁠ “Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions” by Nina BickellDisclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of classical Hodgkin Lymphoma.Our GuestDr Lemieux is a Hematologist at the Centre hospitalier universitair de Québec-Université Laval. He is also a member of the immunocellular therapy network fellowship program at Université Laval. This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our GuestDr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this episode, we review the high-yield topic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hodgkin Lymphoma⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Erin Cummings is still going strong despite being diagnosed with Hodgkin lymphoma in 1972.  At age 15, she noticed a lump on her throat and another on her chest.  That led to a diagnosis of Stage 3B Hodgkin lymphoma.  She was shocked at her diagnosis but initially had trouble putting into perspective just what she was up against because she cancer was something suffered by old people.  Even though she achieved survivorship, she still deals with residual side effects from her treatment regimen.  Nonetheless, Erin has gone on to compete in eight marathons and has established a nonprofit which seeks to aid long-term survivors who also deal with the late effects of cancer treatment.   Erin Cummings of Vineyard Haven, Massachusetts was a freshman in high school when she saw that she had a lump on her throat and on her chest.  She didn't think much of them until her sister saw them and brought it to the attention of their mother.  Erin was taken to a nearby hospital and a week later, she was diagnosed with Stage 3B Hodgkin lymphoma.  She said she benefitted from not knowing much about cancer because she thought it was something by old people and wouldn't pose a problem for her.   This was in 1972, and available treatment options were much different than those available today.  Those options included cobalt radiation treatment, surgery, and a new protocol still considered to be in an experimental phase called chemotherapy.  Erin's parents didn't want her having anything to do with chemotherapy and temporarily considered taking her to Mexico to be treated with laetrile.   Erin underwent a lymphangiogram to determine the exact location of the cancer.  After that came full body radiation, surgery to remove her appendix and a form of chemo called MOP chemotherapy.   She said the side effects of the radiation and the chemotherapy were nasty, but there was also a difficult emotion piece.  Erin said in those days, people thought that cancer was contagious.  As a result, her friends were told by their parents to neither touch her nor get near her.  This combined with Erin being a teenager made her demoralizing cancer experience ever worse.   However, Erin Cummings got through the treatment and became cancer-free five years later, in 1977.  At the ten-year mark, she decided it was time to take control of her body, trained for, and eventually ran in her first marathon.  Before she concluded her competitive running, Erin was in eight marathons in Boston and New York City.   Because she is still encountering the late effects of her cancer treatment and has met others in the same position, Erin established Hodgkin International, a nonprofit which provides help to people around the globe experiencing similar late effects.   Additional Resources:   Support Group:   Hodgkin International: https://www.hodgkinsinternational.org     

To have your question featured in a future video, please email: questions@drmdc.health Please include at least: Age, Weight and as much history as possible.

To have your question featured in a future video, please email: questions@drmdc.health Please include at least: Age, Weight and as much history as possible.

In this week's episode we'll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma. Featured Articles:Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaIFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCDGenetic alteration of class I HLA in cutaneous T-cell lymphoma

This year, Kingston McCaskey and his family will have a Christmas like no other. On Dec. 19th, Kingston rang the bell of hope at Children's of Birmingham, signaling he was cancer free. “We got an early Christmas gift,” Santana McCaskey said. “My son won, not cancer!” McCaskey and her 8-year-old son, Kingston, have been on an emotional roller coaster since Kingston was diagnosed with Hodgkin Lymphoma, Stage 4B in July. Early diagnosis of childhood cancer can be difficult. Kingston's problems actually started in 2nd grade with what they thought was asthma. After testing in July 2024, Santana received a call...Article Link

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.htmlb) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.htmlc) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html2. DLBCL: a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.htmlb) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.htmlc) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html3. Follicular Lymphoma: a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.htmlb) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract4. CLL: a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html5. Hodgkin Lymphoma: a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

In today's episode, we had the pleasure of speaking with Alex F. Herrera, MD, about key safety and efficacy findings from the phase 3 SWOG S1826 trial (NCT03907488) evaluating nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (N+AVD) vs brentuximab vedotin (BV) plus AVD (BV+AVD) in adolescent and adult patients with stage III or IV advanced-stage classic Hodgkin lymphoma. Herrera is chief of the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation, as well as the associate medical director of the Briskin Center for Clinical Research and an associate professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. After 2.1 years of follow-up (range, 0-4.2), N+AVD prolonged median progression-free survival (PFS) and had a more tolerable safety profile compared with BV+AVD. The 2-year PFS rate with N+AVD was 92% (95% CI, 89%-94%) vs 83% (95% CI, 79%-86%) with BV+AVD (HR, 0.45; 95% CI, 0.30-0.65). Notably, the benefit with N+AVD was consistent across diverse patient subgroups enrolled in the study. In our exclusive interview, Dr Herrera expanded on the rationale for conducting SWOG S1826, detailed key data showing sustained benefit and safety with N+AVD, and explained how these results support the use of N+AVD as a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Australian Maria Esguerra tells us that it's still difficult to speak about her personal experiences as a second-generation survivor of The Children of God cult. In this episode of The Influence Continuum, we explored the challenges of breaking free from cults and how those who become part of society's natural defense system against cult indoctrination and authoritarianism help to free others. She traced her story back to a childhood of illnesses that mainly went untreated. “I had measles, chicken pox, mumps, malaria, every imaginable childhood disease, lots of parasites,” she said. Her father would eventually die when she was only four years old from Hodgkin Lymphoma, a form of cancer considered to be largely curable. She explained that in The Children of God cult, medical care was avoided as illnesses were considered the fault of the person or as “God judging you.” Maria is now a psychologist and Director of Assessable, an organization dedicated to serving people with disabilities. This is an especially commendable achievement in that her early life was shaped by her parent's involvement in The Children of God cult. We discussed the experience of raising children within the cult and what ultimately pushed Maria to leave. One of the critical factors in her decision was her son's battle with meningitis, which left him in a coma at a medical research center for ten days, resulting in a lifelong brain injury. While in Africa, Maria became pregnant again and endured harsh conditions. Upon returning to Australia, she resolved to create a new reality for her children—one rooted in safety and love, something she had not been given. Maria is an inspiration for everyone! Learn more about Steven Hassan and Freedom of Mind Resource Center. Visit freedomofmind.com Learn more about your ad choices. Visit megaphone.fm/adchoices

We are happy to welcome Erin Barth-Dwyer of the band Overheard to the show. Erin introduces us to her beautiful 75 lb mixed-breed girl Garbo who came into her life in 2018 shortly after beating Hodgkin Lymphoma. Garbo provides emotional support, humor and has completely transformed Erin into "one of those crazy pet parents". Overheard just released their debut album Intertwined on October 25th on Dromedary Records and is available on vinyl, CD, and your preferred streaming platform.   Erin gave this week's shout out to Dizzy's Doggie Daycare, a bonded and insured pet sitting company located in the Hudson Valley who prioritize socialization, enrichment and group play in a safe environment for your dog with large indoor and outdoor areas. To learn more visit dizzysdoggiedaycare.com  For pics and clips of Erin and Garbo follow us on Instagram at rockerdogpodcast

In this episode, Bernie and Anthony are joined by two special guest expert hematologists: Dr. David Russler-Germain Dr. Tycel Phillips We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired? Stay tuned to find out!

In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm.nih.gov/39413375/5. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html6. Single-agent BV for older adults with Hodgkin: https://ashpublications.org/blood/article/142/Supplement%201/4435/503453 

Alex F. Herrera, MD, City of Hope Medical Center, Duarte, CA Recorded on June 27, 2024 Alex F. Herrera, MD Associate Professor Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation Associate Medical Director, Briskin Center for Clinical Research & City of Hope Duarte Clinical Trials Office City of Hope Medical Center Duarte, CA In this episode, Dr. Alex Herrera from City of Hope explores the intricacies of Hodgkin lymphoma, from diagnosis and monitoring techniques to treatment goals and options. He discusses emerging therapies, including the significance of clinical trials, strategies for managing side effects, long-term effects of treatment, and resources for healthcare professionals, patients, and families. Tune in to learn more today!

In this episode of Cancer Actually F**king Sucks, Amanda Paul shares her experience as a stage four classical multicellularity Hodgkin lymphoma survivor with Abigail. Amanda reflects on her life as a busy high school junior, filled with competitive dance and friendships, until her diagnosis prompted a significant shift in her perspective. She describes the challenging path to her diagnosis, marked by persistent itching and misdiagnoses that left her feeling frustrated. Despite these obstacles, Amanda took charge of her health, advocating for herself and ultimately suspecting cancer before receiving confirmation. Throughout their conversation, Amanda emphasizes the importance of mindset during her experience. She discusses how the situation, while difficult, forced her to slow down and reassess her priorities, leading to personal growth. When she finally received her diagnosis, Amanda felt relief, as it validated her struggles and allowed her to begin treatment. Amanda's story highlights resilience, self-advocacy, and the value of a supportive community. Her experience serves as a reminder that even in tough times, there is space for hope and progress. It would mean so much to the podcast if you would rate and review us on Spotify and Apple Podcasts. And follow us on Instagram at @canceractuallysuckspod for more inspiring stories! If you'd like to share your story in a future episode, we'd love to hear from you! Email us at canceractuallysucks@gmail.com.

Learn about a study in NEJM which found no significant benefits from discontinuing beta-blocker therapy in MI patients, gut microbiota's potential influence on hematologic cancers and, data from ESC Congress 2024 suggesting that catching up on sleep during weekends may reduce heart disease risk by up to 20%.

“With cord blood, hope really knows no bounds.”Diane Paradise is living proof that cord blood transplants cure the incurable. Diagnosed with a rare form of Hodgkin Lymphoma at only 24 years old, Diane fought an extremely hard fight as it returned five more times before age 42. It had now become stage 4B and metastasized to her bone marrow. With no other options, Diane was given hope through a clinical trial. She eradicated all of her sick marrow through aggressive chemotherapy and then was given a new blood type through a cord blood transplant from two different donors. 24 days later, after almost two decades, Diane was cured. She has just celebrated her 10th year of being cancer-free and has committed her life's work to spreading education about the hope behind what banking your baby's cord blood after birth can do for your family. Meagan and Diane talk about what cord blood banking is, how to enroll, how much it costs, and where you can find all of the information you need about this lifesaving procedure. July is Cord Blood Awareness Month and Cryo-Cell is offering a free seminar on Wednesday, July 31 2024 at 1:00 PM EST. Register at https://lp.cryo-cell.com/fuller-paradise-seminar. Cryo-Cell's WebsiteNeeded WebsiteHow to VBAC: The Ultimate Prep Course for ParentsFull Transcript under Episode Details Meagan: Hey, hey everybody. Today's episode is a little different from the norm. We are actually going to be talking about cord blood banking. We have my friend Diane on the podcast. Hello, Diane. Diane: Hello, hello. Meagan: It's so good to see you again. She and I met for the first time actually in January of this year, 2024 at a doula retreat and she was there speaking at this retreat about cord blood banking. Cord blood banking for me wasn't actually a new topic because I had spoken to another company a little while ago about it but there was something extra unique and extra special about Diane and Cryo-Cell is the company that she works with that I was like, We need to share more about this. First of all, her story which I'm sure she'll share a little bit more about, is incredible. So today, we actually normally would do a review, but I really want to soak up the time with Diane because I know her time is so precious. After the intro, we are going to dive right into what this is even about. Meagan: Okay, you guys. Like I said, we have our friend Diane. Diane is a 29-year, six-time cancer survivor. After fighting a rare and uncurable Hodgkin Lymphoma for nearly two decades, a cord stem cell transplant saved her life. You guys, when she was sharing her story at this retreat, it was so insanely amazing and heartbreaking at the same time. So many things that she's been through. It says, “This past December, she celebrated her 10th transplant re-birthday. For many years, Diane was a survivorship educator helping women living with cancer and chronic illness. Today she is spending time on the side of the cure educating expectant parents, birth workers, and obstetricians on providing the potential of cord blood for Cryo-Cell International, the world's first cord blood bank.” Diane, welcome to the show. Seriously, I am so excited for you to talk more about this with our listeners because we do have expectant parents. We do have OB/GYNs and midwives and birth workers and this really is a unique thing and it's something that is so powerful. I know because I've heard your story so I'm just going to turn the time over to you. Diane: Thank you so much, Meagan. First of all, I know your audience is varied but for the expectant moms out there, I just want to say congratulations. I can only imagine the mix of emotions they are feeling right now and one of them is probably a profound sense of hope and anticipation. So for me, hope was two units of cord blood stem cells hanging on an IV pole on December 3, 2013. So let me step back a bit just so everybody can understand. I was diagnosed at 24 years old with that rare, incurable form of Hodgkin Lymphoma. It was back in 1994. I think about that. Wow, I'm aging and I love it. The alternative wasn't great. Meagan: But you're still so young. Diane: I am. I am.I was told that this was incurable and that it would keep coming back. It would be more and more aggressive. The chemo would become less effective over time and the intervals between when it came back would get shorter. That's exactly what happened. It came back at ages 31, 35, and 38. It became really aggressive at age 40. What I mean by that is that it went from stage 2B to 4B. It had metastasized into my bone marrow. I couldn't walk. I couldn't drive. I couldn't take care of myself. I couldn't even take care of myself alone. Thankfully, I went back into remission around the spring of 41, but it came back a year later at age 42. I spent about a year and a half going through different types of chemotherapy trying to get it back into remission and that's when the idea of a transplant came up because quite honestly, it was my last chance. It was my last hope. It was in my bone marrow. It was time to either going to heal or it wasn't. So I ended up in a major hospital and we originally had started looking at bone marrow transplant. We were looking at what they call a half-match and they were going to use my sibling. Now, my siblings aren't ideal donors. They are older than I am and the ideal donor is 18-35. At that point, I was 43 so I was a year and a half into it. I was 43 so that tells you how much out of the ideal age range my siblings were. Then they called me and said, “Oh hey, we have a clinical trial going where we are going to be comparing the side effects of cord blood versus bone marrow and the effectiveness.” I was like, “I don't understand. What's the difference?” They said, “Bone marrow is educated stem cells. They are educated stem cells. They've been exposed so any virus that your donor has or has had, when you receive that donation as your own stem cells, you will have been exposed to that whereas cord blood which is taken after the umbilical cord is clamped and cut is pure and uneducated. It has a higher rate of engraftment. It has a lower rate of graft versus host disease which is where your body thinks the stem cells are the enemy. Then it really doesn't have much of a chance of a virus being there, a latent virus.” I went ahead and said, “Yes. Hello, I'll take that pure, uneducated. I've had a failing immune system for 19 years at this point. Yes. I'll take that clean, clear, beautiful, pristine cord blood stem cells.” So I went to the hospital. It was around November and I had to do a lot of the pretesting. I went through six days of really intense chemotherapy and one day of radiation to eradicate my own bone marrow, the sick bone marrow. Then I received on December 3, 2013, two donor stem cells. One was from Germany and one was from Michigan. About, it was a few weeks later. It was a few weeks later when they pull a blood test to see where are you on the engraftment. Is there a little bit of one of the donors? And I want to step back. The reason that there were two donors– if I were a child, I would only need one donor, but I'm an adult. That's a lot of bone marrow that has to go in and graft and replicate in order to ingraft for an adult basically. That's why I had two of them. It kind of creates a survivor of the fittest. It creates an environment for faster cell engraftment. So then I had the blood test done 24 days later. After 19 years of battling incurable cancer, I was 100% grafted to the Michigan baby in just those 24 days. Meagan: Isn't that incredible? Diane: It really is. I was cured by cord blood in 24 days. Meagan: 24 days after years and years. Diane: Almost two decades. Meagan: Yes. Diane: Yes. So think about this. I want you to really think about this. What is often tossed as medical waste is what saved my life. Meagan: I encapsulate placentas, the actual placenta itself and there will be so many times where people are like, “Why would you do that? That is garbage.” They literally say that. They think that. Placentas are garbage, but look at what it's done. It saved your life. Diane: Well, the cord blood did, yes. Meagan: The cord blood which I understand they can throw the placenta away after they get the cord blood out. Is that correct? Diane: So what we do with cord blood is that after it is clamped and cut, they actually insert a needle and draw the rest of the cord blood out because the placenta continues to pulse as if the baby is there for up to 30 minutes. That's the stem cells that we are collecting. Now, if we were to collect the cord tissue that's after the placenta has been delivered, we will cut and collect the cord tissue if that's something that the parent is interested in, yes. Meagan: Gotcha. Diane: Yes. So I ended up with a new blood type, just so you know. Meagan: Oh yes, I remember you saying that. Diane: Remember? I remember you liked that comment a lot when we talked about it. Meagan: A whole new blood type. The fascinating thing is even your immune system we talked about how it started over. Diane: Yeah, I had new baby immunizations. I'm 43 years old and 44 years old and getting immunizations as if I never had them. Meagan: Yeah. Diane: I just find that so fascinating. Meagan: It is so fascinating. Diane: So fascinating. Meagan: It is. Okay, so cord blood isn't being used a ton. Diane: It is. It is. Meagan: Sorry, it is being used a ton. Diane: A lot more than people know, a lot more than people know. Meagan: This is my thing is that it's not being talked about. Diane: Bingo, ding ding ding. There you go. Meagan: Let's go into that. Diane: Yes. It's funny because even I found a transplant video from the day of the transplant where I did a vlog to my family and friends and I talked to them about these two women who selflessly donated their cord blood and how it would potentially save my life or potentially could save my life. I was like, “I don't even know how they do that.” The video was really funny. What I realized was once I got done with it, I went down this rabbit hole of, I need to know more. Once it cured me, I wanted to know everything. Meagan: I'm sure. Diane: What I found was there was a lot of information out there and it's being used in a lot of ways but there's also misinformation. You had mentioned that I was a survivorship coach leading up to this and I was until I moved to Tennessee and I just decided I didn't want to continue that and I wanted to be on the side of the cure and for me, that was cord blood. Fast forward to today, I am working for Cryo-Cell International and now, I can recognize and help people with the misinformation and myths surrounding cord blood banking. You talked about it not being used. That is simply not true. We just don't know about it. It is actually an FDA-approved treatment for nearly 80 different diseases including blood cancers, and anemias– we have a whole list on our website but there have been 50,000 transplants worldwide and there are 175 active clinical trials for things like autism, multiple sclerosis, cerebral palsy, adult stroke, Alzheimer's, dementia, Type 1 diabetes, Parkinson's– because what it is, cord blood is rich. I don't want this to be a big science class lesson, but it's good for people to understand because we have two different things here. We have cord blood and we have cord tissue. Cord blood is what is called a metapoetic stem cell and that is what creates all of the cells in your blood and immune system which is why it was able to replace my stem cells with my donor's. They are a perfect match for the baby. They are a 50-75% chance of a match for a sibling and there are a lot of sibling transplants and an acceptable match for parents. Now, the other side of it, the cord tissue, is a different type of stem cell which is the mesenchymal stem cell. They do something a little bit different. That's in the Wharton's Jelly so they are capable of becoming structural and connective tissues like bone, fat, and cartilage, and they can modify immune functions to help treat autoimmune diseases such as arthritis and diabetes. I recently listened to a doctor out of UC Davis. Her name is Dr. Farmer and she used the stem cells from cord tissue on the spine of a baby with spina bifida in utero. She did the surgery in utero and closed up the opening where the spinal cord was exposed and the baby came out wiggling their toes and moving legs. Pretty amazing. Meagan: Wow. Diane: Yeah. And there's a lot being done with this. There are over 100 active clinical trials for ALS, rheumatoid arthritis, lupus, Type 1 diabetes again, MS, Crohn's, and spinal cord injuries– I mean, there are just so many active clinical trials for different diseases out there. It is being used. Cord blood is being used and cord tissue is in active clinical trials as well. Meagan: Wow. So especially for our pregnant mamas and expectant parents or even birth workers wanting to share this information with their clients, what is the process to do this? We know a lot of the benefits right here. We just went through so many of these benefits. What is the process of getting started? What I think is pretty cool about Cryo-Cell is that they can send the kit to you. I saw the kit you have brought as an example. Can you walk listeners through what it's like in case they are interested in doing it both physically on what the steps are and even financially if we can talk a little bit about that? Diane: We can.Meagan: Then storage-wise, how long? There are so many questions. Can we talk about that process? Diane: Absolutely. Absolutely. Okay. I'm trying to think of where we should start with this. There are so many questions you just asked me there. Meagan: Sorry, I just threw a lot at you. Diane: Like, hmm. Where do I begin? Another myth– so if somebody wants to save for themselves, one of the myths we hear is that it's expensive. 10 years ago it was. Now, it's more affordable and Cryo-Cell has, first of all, we have the most amazing kit. You mentioned it. I will repeat that. We have a kit that has a handle on it. It comes to you. You open it up and it has everything right there, the forms for you to fill out, the information for you to give the delivery physician. All of that is right there. When you enroll, you get the collection kit, the shipping, the medical courier, the processing, and testing because after processing, once it arrives back to us, it has to be processed and tested as well as the first year is storage. That price because it has that initial fee in it ranges from $800-2000 whether it is cord blood or cord blood and cord tissue. However, we have a risk-free enrollment so nothing is charged at the time that you enroll. If you decide not to collect, call us and ship the kit back within two weeks and it will be no cost to the expectant parent. Then after that, if they do enroll and we get all of it and it's processed, the annual storage fee runs between $185 and $370. It's $185 for cord blood and then $370 for cord blood and cord tissue. We offer flexed payment plans. We offer monthly specials. There are discounts for returning clients and families with multiple children. We have military discounts for retired and active and also medical professionals. If your friends and family want to purchase gift certificates for you, they can do that as well. We have that ability. The thing that I like the most is that we have a refer-a-friend program. If you are having a baby, your friends are probably having them too. If you refer your friend to us and they become a client, you get a free year of storage and you can get unlimited years of storage using that program. I do want to just take a quick step back with the kit because our kit is like I said, it's special. It has everything in it that you need. We have these– I'm trying to think of what they are called right now. Vacuum packs, they're not vacuum packs. They're insulated packs because it has to stay at a certain temperature. If it's too hot out, those packs will cool the collection down as it's being shipped. If it's too cold out, it will warm them up. It's pretty special. It is definitely a kit and then it also protects up to 30 times longer because of that. Meagan: Yeah. Which I think is a really unique thing about their kit for sure. Diane: Yes. Yes. Meagan: So they've got it no matter what part of the world or what time your baby is born. If it's in wintertime or summertime– Diane: Yes. It's taken care of. Meagan: It's taken care of. You can rest assured. Okay, so they can enroll to be a member. If you do and decide to donate, it gets sent. There's an initial fee but then there is an annual fee which you can easily get for free by referring friends. We talked about it being shared and it can help siblings and things like that. It is there if you need it. For your instance, is it possible to be a match to somebody then does someone call? How does that work? Diane: No, so my donations came from a public bank. Mine were unrelated donors. Meagan: Okay, because that was a clinical thing too, right? Was yours a trial? Diane: It was a trial, but they already knew that cord blood transplants worked. They were just trying to compare the side effects of each– which has lower, graft versus host. Meagan: So it was just being donated from a bank. Diane: Yes, from a public bank. If someone can't afford to private bank for their family, there is the option to donate like what saved me. Meagan: That's where I was getting at. This is perfect. Diane: That is free and that is anonymous. You can give someone a chance at life whether it be through a transplant like I received or through research. Cryo-Cell has public donation sites in Florida, Arizona, and California. If there isn't one in someone's area who is listening, I'm sure you'll put out my contact information and they can contact me directly and I may be able to help them find a way for them to donate. Now, there's a couple of things that I want people to understand about the public donation option. If you can't afford to private bank, this is a great option because the only other option is for it to be medical waste. Let these be the only two options for you and that's why I'm like, contact me. I might be able to help. I want you to understand that I did have two donors. Only one of them was from the United States. They had to go out of the States to Germany to find me a second match. Whether it's bone marrow or cord blood, it isn't easy to find any match when it comes to that type of transplant. If there is a family history of any of the diseases that I mentioned earlier, I really urge people to consider private banking to safeguard your family's health because when you donate, sometimes people think, Well, I'll just donate and it'll be there if I need it. Well, 8 out of 10 units that are donated go to medical waste anyway because of family health history or low collection volume and they are being used daily. The ones that are there are being used daily so most likely, you won't find it if you need the cord blood for your family. Meagan: Right and your family is more likely to be a perfect match, right? Diane: With the matches, it is a perfect match for the baby. It's a 50-75% acceptable match for a sibling and an acceptable match for the parents as well. Meagan: Right, yeah. So pretty awesome chances. Diane: Yes. Yes. Because of the audience, I want everybody to understand because this is probably the #1 myth that I get from parents that I hear a lot. That is that, Well, I want to delay cord clamp so I can't save the cord blood. I want you to know that you can. 10 years ago, that was probably true. Today, if they follow the ACOG recommendation of a 30-60-second delay, you can delay and save. It may yield a smaller collection so basically what that means is it's really crucial to select the best processing method. For instance, our PrepaCyte processing method is more advanced. It provides a cleaner yield and that is what makes it beneficial for delayed cord clamping and saving the cord blood. So if that is truly what they want to do, here's the other thing to know. Remember how I said that you have a risk-free enrollment if you enroll then decide not to collect? If you enroll and you collect and it gets to us and it has suboptimal results, we pick up the phone and call you and talk to you about it. You can decide one way or another if you want to move forward with banking that cord blood. Meagan: Continue. Diane: Yes. And you did ask about how long does this stuff last? Cord blood is living medicine. It is collected. It is processed and it is stored in this amazing five-compartment chamber so you can get multiple uses out of it if maybe it's a treatment protocol and it's not one big transplant necessarily which I think is going to become more and more the way of doing things with cord blood. That's my personal opinion. That's not necessarily the opinion of Cryo-Cell, but I do see that with all of the reading that I've done. Did I answer all of those questions you threw at me? I'm not sure, but I tried. Meagan: Yes, yes. I think you did. You nailed it. Diane: Yes. Meagan: Yes. Yes. Okay, so obviously you chose to work for Cryo-Cell for a reason and you're telling us all of the things about why but is there anything else that you are like, this is literally why I choose Cryo-Cell and why I suggest them? Diane: Yes. When I was doing all of my research, I looked into all of the cord blood banks, but for me, because I was cured by cord blood. This was why I am still standing here. I wanted to work for a company who did more than just banked cord blood. So when I went looking for that and I found Cryo-Cell, I realized that they focus on cord blood education and also cord blood advancement. They are embedded in every facet of the cord blood industry. They have private which is also called family banking. They have public donation sites. They are always seeking out the best technology for our kids and for our storage. I mentioned those temperature packs. I mentioned the five-chamber storage bag and then our premium processing, the PrepaCyte. So we are the world's first cord blood bank, but we don't ever rest on our laurels. Thank you. There's the word. They never rest on their laurels, so to speak. Why do I keep trying to say that word? That's hilarious. They are constantly trying to advance research. They are advancing research. In 2021, Cryo-Cell entered into an exclusive license agreement with Duke University and what that does is it grants us the right to propriety processes and regulatory data related to cord blood and cord tissue development at Duke. This year, I love this. This year, we are opening our first infusion clinic where it will be a site for future clinical trials investigating cerebral palsy, autism, and other neurological conditions. This is what I mean. We don't just collect the cord blood and cryo-preserve it. We are constantly looking for how that can be used. How can it be used to protect the families who have trusted us with their baby's cord blood? And not just us, but they've trusted us and we want to do what's right for them. Cord blood is all we do. We aren't part of a larger business model and that's what makes our quality and our level of customer service unmatched. I knew Cryo-Cell was who I wanted to work for and I'll be honest with you. The story behind how this all happened was honestly the stars aligning and I happened to be in the same room with someone who worked there. I had a conversation and a few months later, this is where I ended up. I couldn't be happier. This company is– Meagan: Life-changing, literally. Diane: Yes. Life saving. Meagan: Lifesaving, yeah. Okay, so tell everybody where they can enroll and find more information because on the website, there's a lot of really great information. There's more on why, pricing, they go into the cord tissue. They talk about private versus public so all of the things that you've been touching on. They've got all of these things, a Q&A. There is a really, really great amount of information. Where can they find you? Where can they find the website? How can they enroll and all of the things? Diane: If they want to know more or are ready to enroll, they can go to our website which is cryo-cell.com and they can either chat with one of our incredible cord blood educators. They can click to enroll. Like you said, everything that they are curious about is there. If they want to reach out to me personally, I have an Instagram account for Cryo-Cell which is called @curedbycordblood. I have all of my contact information there. Meagan: Okay. I'm going to write that down right now so we can make sure to have it in the show notes. You guys, it's super easy in case you forget anything. Just scroll in the show notes. Click the link and you can go read more about how you can definitely start cord blood banking for yourself or like she said, even donate to the public. Diane: Yes. Yes, or for research. Can I just end with one thing for these expectant parents? Meagan: Yes, of course. Diane: Banking cord blood is a once in your baby's lifetime opportunity. You don't want to miss it. If you have questions, call us. When I tell you we have the greatest educators in the industry, I mean it. Every bit of it, I mean it. They can answer all of your questions. All I ask is that no matter what you decide, please don't let it go to medical waste because, with cord blood, hope really knows no bounds. Meagan: Thank you so stinking much for joining us today and sharing this seriously invaluable information. It is so important and it can really benefit so many people. So thank you so much.  Diane: Thank you for having me.  ClosingWould you like to be a guest on the podcast? Tell us about your experience at thevbaclink.com/share. For more information on all things VBAC including online and in-person VBAC classes, The VBAC Link blog, and Meagan's bio, head over to thevbaclink.com. Congratulations on starting your journey of learning and discovery with The VBAC Link.Support this podcast at — https://redcircle.com/the-vbac-link/donationsAdvertising Inquiries: https://redcircle.com/brands

Sixty patients with the rare non-Hodgkin Lymphoma blood cancer, will be given CAR-T Cell therapy which reprogrammes their immune cells to recognise and kill cancer cells. Cancer patient David Down spoke to Ingrid Hipkiss.

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/BispecificLymphoma).

In this episode, we speak with Dr. Matthew Matasar of Rutgers Cancer Institute, and Elizabeth Stone, who was diagnosed with… The post Patient-Doctor Perspectives: Resilience in Relapsed/Refractory Hodgkin Lymphoma first appeared on The Bloodline with LLS.

In this episode, we speak with Dr. Matthew Matasar of Rutgers Cancer Institute, and Elizabeth Stone, who was diagnosed with… The post Patient-Doctor Perspectives: Resilience in Relapsed/Refractory Hodgkin Lymphoma first appeared on The Bloodline with LLS.

An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the conference, Oncology Times reporter Peter Goodwin met up with Peter Borchmann, MD, PhD, the lead author of the new research and Chair of the German Hodgkin Study Group at the University Hospital of Cologne in Germany.

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics: Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostConf24/Lymphoma).

Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in Hodgkin lymphoma with Andrew Evens, DO, MBA, MSc, Director of the Lymphoma Program and Associate Director of Rutgers Cancer Institute; Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in Division of Hematology at the Mayo Clinic; and Jane Winter, MD, a Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine.

Welcome to another episode of That Cancer Conversation! April is Teenage and Young Adult Cancer Awareness Month, where charities and the young people we support come together to raise awareness of the unique challenges of having cancer during some of the most intense years of your life. In this episode Sophie speaks to Shaumya, who was 18 years old and getting ready to go to medical school when she was diagnosed with Hodgkin Lymphoma, right in the middle of the COVID-19 pandemic. Since joining the The Royal Marsden Youth Forum, Shaumya has been an advocate for age-appropriate care for teenagers and young adults. She co-hosts her own cancer podcast, Afterthoughts: The Teenage Years, highlighting teenage voices, and is also part of the Cancer Research UK for Children & Young People Patient Insight Panel, where she helps make sure people affected by cancer are always at the heart of our work. Recently, she's helped choose our new logo and spoken to researchers from across the UK at our first Children's and Young People's Cancer Research Conference. To read more cancer stories visit https://news.cancerresearchuk.org/ Hosted on Acast. See acast.com/privacy for more information.

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Commentary by Gabriel Aleixo

Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics:  Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00) Follicular and Mantle Cell Lymphoma (7:17) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10) CME information and select publications   

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Lymphoma).

Dr Lunning sits down with Alex Herrera, MD, of City of Hope, to discuss the frontline management of Hodgkin lymphoma, including the rationale for the SWOG 1826 trial, the collaborative efforts between pediatric and adult oncologists that led to the successful initiation of this trial, potential future directions for this research, and more.

In this week's episode we'll discuss the findings from a prospective trial of brentuximab vedotin with dacarbazine or nivolumab in older patients with classical Hodgkin lymphoma, learn more about CD20 antigen loss as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas, and discuss the role of trogocytosis in red blood cell antigen loss.

Joining host Chadi is a trio of esteemed guests – Drs. Andy Evans, Matt Maurer, and Susan Parsons – of the HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) Consortium. In this riveting conversation, they delve into the consortium's pioneering efforts, bringing together an international team of experts to scrutinize the multifaceted dimensions of Hodgkin lymphoma, spanning prognosis, epidemiology, treatment, survivorship, and health outcomes across all age groups. The discussion circles around consensus protocols for treatment, referral pathways, and clinical trials, probing the necessity of transplants in the era of novel therapeutics and the creation of predictive models tailored to individual patient needs. Tune in to hear about the meticulous efforts invested in building the HoLISTIC portal, automating data migration, and navigating the challenges and progress in predictive modeling for treatment selection, response, and failure. This episode offers a captivating exploration of how collaboration, technology, and data analysis converge to shape the future of Hodgkin lymphoma care. Find out more about the HoLISTIC Consortium. https://www.hodgkinconsortium.com/ Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

The first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium. Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what the effort means for both clinicians and patients.

OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion! Abstracts Discussed! SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study) Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20

Featuring perspectives from Dr Jeremy S Abramson, Dr Stephen M Ansell, Dr Nancy L Bartlett, Dr Jonathon B Cohen, Dr Jonathan W Friedberg and Dr Brad S Kahl, including the following topics: Introduction (0:00) Evolving Role of Novel Treatment Strategies in Follicular Lymphoma (FL) — Dr Friedberg (7:20) Integration of CAR (Chimeric Antigen Receptor) T-Cell Therapies and Bispecific Antibodies into the Management of FL — Dr Abramson (33:08) Up-Front Treatment for Mantle Cell Lymphoma (MCL) — Dr Kahl (58:54) Therapeutic Sequencing for Patients with Relapsed/Refractory (R/R) MCL — Dr Cohen (1:23:46) First-Line Treatment Strategies for Hodgkin Lymphoma (HL) — Dr Bartlett (1:45:42) Current and Future Management of R/R HL — Dr Ansell (2:18:49) CME information and select publications

BUFFALO, NY- December 20, 2023 – A new #review paper was #published in Oncotarget's Volume 14 on December 12, 2023, entitled, “Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability.” Classic Hodgkin lymphoma (CHL), which accounts for 90–95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10–15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted mainly of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem-cell transplantation. However, improved understanding of the pathobiology of CHL, coupled with the introduction of novel agents, has markedly changed the treatment landscape in the past decade. Although refractory or relapsed CHL continues to be challenging, the therapeutic landscape is undergoing profound changes brought about by novel agents, particularly brentuximab vedotin and immunotherapy. In this new review, researchers Flávia Dias Xavier, Danielle Leão Cordeiro de Farias, Abrahão Elias Hallack Neto, Glaciano Nogueira Ribeiro, Marco Aurelio Salvino de Araujo, Thiago Xavier Carneiro, and Otavio Cesar Carvalho Guimarães Baiocchi from Hospital Universitário de Brasília-Universidade de Brasília/Ebserh, Hospital DF Star, Hospital A Beneficência Portuguesa de São Paulo, Universidade Federal de Juiz de Fora, Clínica Hematológica/Grupo Oncoclinicas, Universidade Federal da Bahia, Instituto D'Or de Pesquisa e Ensino, Universidade Estadual do Pará, Universidade Federal de São Paulo, and Hospital Alemão Oswaldo Cruz discuss the most salient treatment options for adult patients with refractory or relapsed CHL, with a special focus on the Brazilian healthcare setting, which is constrained by inherent characteristics of this system. “In the attempt to balance efficacy, safety and tolerability, practicing physicians must rely on clinical trials and on results from real-world studies, and use their own point of view and experience, as well as patient characteristics and previous therapy, to make treatment decisions for refractory or relapsed CHL.” DOI - https://doi.org/10.18632/oncotarget.28541 Correspondence to - Flávia Dias Xavier - flavia.xavier@unb.br Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28541 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, brentuximab vedotin, drug therapy, hodgkin lymphoma, nivolumab, pembrolizumab About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)  https://ash.confex.com/ash/2023/webprogram/Paper191921.html Chronic Lymphocytic Leukemia 1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063 2. Ibrutinib retreatment in Phase 2 CAPTIVATE study: https://ash.confex.com/ash/2023/webprogram/Paper187128.html Hodgkin Lymphoma 1. S1826 outcomes in older adults:  https://ash.confex.com/ash/2023/webprogram/Paper180114.html Diffuse Large B-cell Lymphoma 1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180381.html 2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper177588.html

Check out this week's QuadCast as we highlight why radiation therapy is important in Hodgkin Lymphoma, the fact that invasive lobular carcinoma may be sneakily more aggressive than their ductal counterparts, and more! QUADSHOT

Welcome back to the Better with Running Podcast! In this episode, we're joined by two incredible guests who share their inspiring running journeys. Our first guest -Norah Armstrong - From Schoolyard to XCR Norah Armstrong, Chris's wife, recounts how they first met in the school quadrangle and how Chris introduced her to the world of running, making her a dedicated fan. Despite never participating in organized sports in high school, Norah recently celebrated her 350th parkrun, a testament to her decade-long dedication to running. We hear about Norah's early struggles with running and how she persevered to become a seasoned runner. Norah's journey has taken her from being a parkrun regular to embracing other fun runs and even taking on the competitive cross country scene. Nathan Contin - Overcoming Adversity and Achieving Personal Bests: Meet #teamrun2p athlete Nathan Contin, who started his running journey in 2022 using a running app, progressing from the couch to completing a 10km. Under the guidance of Run2PB Coach Jack Davies, Nathan has achieved remarkable progress, setting personal bests across various distances, including 5k, 10k, half marathon, and full marathon this year. Nathan shares his journey of overcoming health challenges, including battling Hodgkin Lymphoma, and celebrates being four years in remission. We dive into the highlights of Nathan's recent marathon, where he achieved an impressive 20-minute personal best at the Melbourne Marathon. and also gain insights into Nathan's favorite training sessions and the valuable lessons he's learned along his running journey. Don't forget to follow us on social media and leave a review if you enjoyed this episode! Tune in next week for more inspiring stories on the Better with Running Podcast. Happy running!

In this week's episode, we'll learn how the diversity of gut microbiota predicts mortality and acute graft-versus-host disease in pediatric allogeneic transplant recipients. Then we'll discuss complement inhibition in patients with complement-mediated atypical hemolytic uremic syndrome. Finally we'll learn how PD-1 plus HDAC equals responses in previously treated Hodgkin lymphoma, specifically that response rates were encouraging in a heavily pretreated cohort, even among patients with PD-1 refractory disease.  

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hodgkin Lymphoma ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

In this week's episode, we'll learn about long-term outcomes with pembrolizumab in relapsed/refractory classical Hodgkin lymphoma. Next, what's behind the accumulation of toxic free alpha-globin in beta-thalassemia? Finally, a road map for managing CAR T cell hematologic toxicity. 

Tung Wynn, MD, University of Florida, Gainesville, FL and Braulio Hernandez Recorded on June 10, 2023 Join Dr. Tung Wynn from the University of Florida, and Braulio Hernandez, a childhood cancer advocate and AYA survivor of Hodgkin Lymphoma, as they discuss the unique experiences of adolescents and young adults from active treatment to survivorship. Dr. Wynn and Braulio reflect on the physical and psychosocial long-term and late effects of treatment, strategies to support survivors and their families, survivorship guidelines, follow-up care coordination, and resources for clinical staff and for survivors. Listen to this engaging conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc., Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.

In this week's episode, we'll learn more about what whole genome sequencing reveals about genetic subtypes of follicular lymphoma and risk of transformation, discuss the role of the lipid mediator, resolvin D4, in infectious neutrophil deployment and emergency granulopoiesis, and learn more about Hodgkin lymphoma-directed therapy and the role of PET in early-stage nodular lymphocyte-predominant Hodgkin lymphoma. 

Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/MTPLymphoma23/)

This week, the girls are joined by creator, cancer survivor and close friend Georgie Swallow. At 26, Georgie was diagnosed with stage 4 Hodgkin Lymphoma. Without any time to think, she had to jump into chemotherapy to save her life. The only way to get through the exhausting and devastating process was to remain positive and power through. Now, after a second diagnosis and treatment, Georgie is living life at her healthiest. However, this doesn't mean that cancer doesn't still cause her daily issues. From infertility to gut health issues, Georgie marches through each day, and as the girls say, all while exuding sunshine. Georgie uses her platform to spread joy, body confidence and share what life is like after cancer.Follow Georgie on Instagram @georgieeswallowFollow us on Instagram @shouldideletethatEmail us at shouldideletethatpod@gmail.comProduced & edited by Daisy GrantMusic by Alex Andrew Hosted on Acast. See acast.com/privacy for more information.